Joyce Thompson, MD

Articles by Joyce Thompson, MD

Extending Principles Learned in Model Systems to Clinical Trials Design

ByPeter J. Houghton, PhD,Joyce Thompson, MD,Victor M. Santana, MD,Wayne L. Furman, MD,Henry S. Friedman, MD

August 1st 1998

Clinical results with irinotecan (CPT-11 [Camptosar]) and other camptothecin derivatives in various cancers, although encouraging, have fallen short of the expectations predicted by preclinical models. One proposed

Latest Updated Articles

Extending Principles Learned in Model Systems to Clinical Trials Design
August 1st 1998

Joyce Thompson, MD

Articles by Joyce Thompson, MD

Extending Principles Learned in Model Systems to Clinical Trials Design

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer

Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications

NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing

Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial

EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC